Actuate Therapeutics Inc (ACTU) Stock Price, Quote & News

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric l...

Industry: Biotechnology

Sector: Healthcare

Phone: 817 887 8455

Website: actuatetherapeutics.com

Address:

1751 River Run, Suite 400, Fort Worth, United States

justiceforb_85 May. 13 at 1:56 AM

$ACTU positive developments include oral formulation of elraglusib. If there is preclinical evidence for synergy with RAS inhibitors, the company would be on significantly better footing. Ewings signal is real but TAM quite small.

0 · Reply

focafoca99 May. 12 at 1:53 AM

$ACTU kicks off its IND FDA clearance to begin a Phase 1/2 study of elraglusib.

0 · Reply

justiceforb_85 May. 11 at 8:01 PM

$ACTU absurd drop. Added. Look forward to oral erlaglusib and preclinical data with RAS inhibitors.

0 · Reply

ggabel7 May. 11 at 7:38 PM

how come retail didn’t see $ACTU FDA news today ? volume will come $MRAM $NVTS $INTC $NOK

0 · Reply

ggabel7 May. 11 at 7:36 PM

wow looks like retail did see the fra news today and HCWainwright reiterates buy ratting for $ACTU volume will send it let’s see what happens $MRNA $IREN $JNJ $MRK

0 · Reply

Dan8406 May. 9 at 1:50 PM

$ACTU Just a few things about Dr. Huber! Dr. Huber has over two decades of experience in the biotechnology sector and has successfully overseen several corporate acquisitions: Mersana Therapeutics: He served as the President and CEO of the company from 2023 until January 2026, when the firm was acquired by Day One Pharmaceuticals. TESARO: He worked here as Chief Medical Officer. Following the acquisition of the company by GlaxoSmithKline (GSK) in 2019, Huber continued to lead clinical development as Vice President. Merck: Between 2012 and 2015, he served as Vice President responsible for oncology clinical research. Academic background: He began his career as an Assistant Professor at one of the world's leading cancer research centers, the M.D. Anderson Cancer Center in Texas.

0 · Reply

justiceforb_85 May. 6 at 9:24 PM

$ACTU do we have any other monotherapy data for elraglusib aside from this prior study (https://aacrjournals.org/clincancerres/article-abstract/30/3/522/733553/Phase-I-Study-of-Elraglusib-9-ING-41-a-Glycogen?redirectedFrom=fulltext)? Combination with GnP for PDAC appears promising though with $RVMD future care would likely involve combining elraglusib with a RAS inhibitor.

0 · Reply

focafoca99 May. 6 at 2:26 PM

$ACTU assigned Dr. Huber to its board, expanding the directors to eight.

1 · Reply

crimsonsunglo Apr. 28 at 3:31 PM

$ACTU moving up on low volume.

0 · Reply

BiotechButterflies Apr. 22 at 8:23 PM

$ACTU a very intriguing set-up here - I'v gotten in!

0 · Reply

Actuate Therapeutics receives FDA clearance for oral elraglusib study

May 11, 2026, 7:00 AM EDT - 2 days ago

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

May 9, 2026, 11:53 AM EDT - 3 days ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ATAI VVOS

May 6, 2026, 8:45 AM EDT - 6 days ago

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

2026-04-30T16:41:48.000Z - 12 days ago

Actuate Therapeutics management to meet with B. Riley

Apr 22, 2026, 7:23 AM EDT - 21 days ago

Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

Apr 14, 2026, 8:45 AM EDT - 4 weeks ago

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

2026-04-13T10:17:08.000Z - 4 weeks ago

Actuate Therapeutics price target lowered to $15 from $20 at H.C. Wainwright

Mar 24, 2026, 7:00 AM EDT - 7 weeks ago

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

2026-03-09T12:57:35.000Z - 2 months ago

Actuate launches research initiative to combine elraglusib, RAS inhibitors

Mar 9, 2026, 8:45 AM EDT - 2 months ago

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Feb 24, 2026, 8:45 AM EST - 2 months ago

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-21T13:56:06.000Z - 3 months ago

Actuate Therapeutics announces plans to expand clinical pipeline

2026-01-12T13:51:27.000Z - 4 months ago

Actuate Therapeutics says Phase 2 study met primary endpoints

Jan 12, 2026, 8:45 AM EST - 4 months ago

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

2026-01-06T13:57:14.000Z - 4 months ago

Actuate announces results from Phase 1 portion of study of elraglusib

$Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers$

Jan 6, 2026, 8:45 AM EST - 4 months ago

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Dec 18, 2025, 8:45 AM EST - 5 months ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

2025-12-15T13:55:21.000Z - 5 months ago

Actuate Therapeutics announces publication of Phase II data for elraglusib

2025-09-22T12:50:20.000Z - 8 months ago

Actuate announces corporate update on regulatory path for elraglusib

Sep 22, 2025, 8:45 AM EDT - 8 months ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

2025-09-10T12:45:51.000Z - 8 months ago

Actuate prices 2.14M shares at $7.00 in underwritten public offering

2025-09-10T12:35:09.000Z - 8 months ago

Actuate Therapeutics 2.142M share Secondary priced at $7.00

Sep 10, 2025, 8:31 AM EDT - 8 months ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

2025-09-09T20:10:46.000Z - 8 months ago

Actuate Therapeutics announces common stock offering, no amount given

Sep 9, 2025, 4:07 PM EDT - 8 months ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

2025-09-02T20:35:57.000Z - 9 months ago

Actuate Therapeutics files $250M mixed securities shelf

2025-08-26T08:45:11.000Z - 9 months ago

Actuate Therapeutics initiated with a Buy at B. Riley

2025-08-06T12:51:12.000Z - 9 months ago

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

INCY

Aug 6, 2025, 8:45 AM EDT - 9 months ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

2025-07-25T20:05:36.000Z - 10 months ago

Actuate Therapeutics files to sell 1.33M shares of common stock for holders

2025-07-17T12:55:30.000Z - 10 months ago

Actuate Therapeutics announces end of Phase 1 portion of elraglusib study

Jul 17, 2025, 8:45 AM EDT - 10 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

2025-06-24T13:26:49.000Z - 11 months ago

Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

Jun 24, 2025, 9:15 AM EDT - 11 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

2025-06-20T12:50:07.000Z - 11 months ago

Actuate reports biomarker, machine learning data from Phase 2 elraglusib trial

Jun 20, 2025, 8:45 AM EDT - 11 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

2025-06-16T12:40:38.000Z - 11 months ago

Actuate Therapeutics announces inclusion in Russell 3000, 2000 indexes

Jun 16, 2025, 8:30 AM EDT - 11 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

May 31, 2025, 4:30 PM EDT - 1 year ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Apr 23, 2025, 10:24 AM EDT - 1 year ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Dec 17, 2024, 8:28 AM EST - 1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Oct 29, 2024, 6:39 PM EDT - 1 year ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

$Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma$

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 5, 2024, 9:10 AM EDT - 1 year ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

justiceforb_85 May. 13 at 1:56 AM

0 · Reply

focafoca99 May. 12 at 1:53 AM

$ACTU kicks off its IND FDA clearance to begin a Phase 1/2 study of elraglusib.

0 · Reply

justiceforb_85 May. 11 at 8:01 PM

$ACTU absurd drop. Added. Look forward to oral erlaglusib and preclinical data with RAS inhibitors.

0 · Reply

ggabel7 May. 11 at 7:38 PM

how come retail didn’t see $ACTU FDA news today ? volume will come $MRAM $NVTS $INTC $NOK

0 · Reply

ggabel7 May. 11 at 7:36 PM

wow looks like retail did see the fra news today and HCWainwright reiterates buy ratting for $ACTU volume will send it let’s see what happens $MRNA $IREN $JNJ $MRK

0 · Reply

Dan8406 May. 9 at 1:50 PM

0 · Reply

justiceforb_85 May. 6 at 9:24 PM

0 · Reply

focafoca99 May. 6 at 2:26 PM

$ACTU assigned Dr. Huber to its board, expanding the directors to eight.

1 · Reply

crimsonsunglo Apr. 28 at 3:31 PM

$ACTU moving up on low volume.

0 · Reply

BiotechButterflies Apr. 22 at 8:23 PM

$ACTU a very intriguing set-up here - I'v gotten in!

0 · Reply

Rolo2024 Apr. 19 at 12:57 AM

$ACTU Biggest worry is the cash burn rate. Only have cash on hand to run until July of 2026. Results are are promising but looks like a stock offering will happen this summer. I might wait until this plays out before buying some shares. I hate dilution.

1 · Reply

RadioIsotope25 Apr. 15 at 11:44 AM

$ACTU

0 · Reply

papibaro Apr. 15 at 3:38 AM

$ACTU new to this stock. saw today’s news. Seemed very positive. Plus, pancreatic cancer is potentially a huge opportunity. For those know the company better, how are their management, finances, and history? Do they have a history of diluting?

0 · Reply

LewisDaKat Apr. 14 at 7:30 PM

$ACTU Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma https://marketwirenews.com/stock/actu/news/actuate-therapeutics-announces-nature-medicine-publi-6349215341264352.html?utm_source=stocktwits

0 · Reply

BioTuesdays Apr. 14 at 2:23 PM

$ACTU has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer (mPC). https://biotuesdays.com/2026/04/14/nature-medicine-publishes-actuates-data-from-trial-of-elraglusib-chemo-in-mpc/

0 · Reply